Melanotan-2: A Research Overview

Introduction

Melanotan-2 (MT-II; also written Melanotan II) is a synthetic cyclic heptapeptide classified as a non-selective melanocortin receptor agonist. The compound was developed at the University of Arizona during the late 1980s and 1990s by a research group that included Victor J. Hruby and Mac E. Hadley, as part of a systematic effort to produce enzymatically stable analogs of alpha-melanocyte stimulating hormone (α-MSH). MT-II has been widely employed as a pharmacological research tool in studies examining the melanocortin system, and it served as the structural precursor to bremelanotide (PT-141), a melanocortin receptor agonist that subsequently received regulatory approval. This article provides an educational reference overview of MT-II's chemical identity, receptor pharmacology classification, regulatory standing, and scientific lineage.

Background

The melanocortin system encompasses a family of endogenous peptide hormones — including α-MSH, β-MSH, γ-MSH, and adrenocorticotropic hormone (ACTH) — all derived by post-translational processing of the proopiomelanocortin (POMC) precursor protein. These endogenous ligands act through a family of five G-protein-coupled receptors (MC1R through MC5R), each with a distinct pattern of tissue expression and functional role [1]. Research interest in the melanocortin system expanded substantially in the early 1990s following the molecular cloning of melanocortin receptor subtypes, work that revealed the multiplicity of pathways governed by this signaling axis [2].

Native α-MSH is a tridecapeptide (13 amino acids) produced primarily in the pituitary intermediate lobe and peripheral tissues. Its biological half-life in plasma is measured in minutes due to rapid enzymatic cleavage, a property that limits its utility as a research tool or therapeutic lead. The Hruby–Hadley group at the University of Arizona undertook a systematic structure-activity program aimed at producing conformationally constrained analogs with greater potency, metabolic stability, and pharmacokinetic tractability.

Chemistry and Structure

MT-II is a cyclic heptapeptide with the sequence Ac-Nle4-c[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH2, incorporating a lactam bridge between the aspartic acid residue at position 5 and the lysine residue at position 10 [3]. This cyclic constraint was a defining synthetic innovation: by restricting conformational freedom within the pharmacophore core (His-Phe-Arg-Trp), the research group was able to identify a bioactive conformation and stabilize it within a compact scaffold.

Several structural features distinguish MT-II from the native α-MSH sequence from which it was derived:

• Norleucine (Nle) is substituted for methionine at position 4, removing a metabolically labile sulfur-containing residue and contributing to stability.
• D-phenylalanine (D-Phe) replaces the native L-phenylalanine at position 7, contributing to both receptor potency and resistance to proteolytic degradation.
• The lactam bridge between residues 5 and 10 forms the defining cyclic topology.
• An N-terminal acetyl (Ac) group and a C-terminal amide (NH2) group further protect against exopeptidase cleavage.

The first preparative solution-phase synthesis of MT-II using an orthogonal protection strategy and carbodiimide-mediated lactamization was described by Ryakhovsky and colleagues in 2008, demonstrating that the peptide could be produced at preparative scale without preparative chromatography [4]. Standard solid-phase peptide synthesis (SPPS) routes have also been applied in research settings.

Pharmacological Classification

MT-II is classified as a non-selective melanocortin receptor agonist, with documented agonist activity at MC1R, MC3R, MC4R, and MC5R [1]. It does not appreciably engage MC2R (the ACTH receptor), consistent with the structural requirement of the full 39-residue ACTH sequence for MC2R recognition. This pan-melanocortin selectivity profile made MT-II a valuable research tool before more receptor subtype-specific pharmacological probes became available.

The compound couples to the stimulatory G-protein (Gs) pathway at each of these receptor subtypes, leading to adenylyl cyclase activation and intracellular cyclic AMP (cAMP) accumulation [5]. Its broad receptor engagement has made MT-II a reliable activator of the overall melanocortin pathway in preclinical research, and it has been employed as a reference compound in studies characterizing the physiological roles of individual receptor subtypes through selective antagonism and genetic approaches [6].

Discovery History

The University of Arizona group built on decades of structure-activity research into α-MSH analogs that began in the 1970s and 1980s. The synthesis and characterization of MT-II as a high-potency cyclic melanocortin agonist was reported in the early 1990s, and the compound's transition from laboratory research tool to clinical-stage compound was marked by the first-in-human pilot phase I evaluation published by Dorr, Lines, Levine, Brooks, Xiang, Hruby, and Hadley in 1996 in the journal Life Sciences [3]. That early clinical report was significant for characterizing MT-II pharmacodynamics in human subjects under controlled research conditions.

Subsequent preclinical and clinical research conducted through the late 1990s and 2000s used MT-II to probe the physiological roles of the melanocortin system. A comprehensive review published in 2006 in Peptides by Hadley and Dorr described the historical milestones of MT-II and related melanocortin peptide therapeutics, situating the compound within a broader translational research lineage [6]. MT-II's structural contribution to the development of bremelanotide represents a direct example of a research tool compound advancing a pharmacological class toward eventual regulatory approval.

Regulatory Status

MT-II has not received approval from the United States Food and Drug Administration (FDA) for any therapeutic indication, nor from the European Medicines Agency (EMA) or equivalent bodies in other major jurisdictions. The compound carries no approved labeling for human use and is classified as a research-use-only material.

The structurally related compound bremelanotide (PT-141; brand name Vyleesi) — derived from MT-II by removal of the N-terminal norleucine residue and addition of a C-terminal hydroxyl — received FDA approval in June 2019 under NDA 210557 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The clinical development of bremelanotide established a regulatory precedent for melanocortin receptor agonism in the therapeutic context, and the structural relationship between the two compounds has been highlighted in published reviews as evidence of MT-II's contribution to the field. Research-grade Melanotan-2 from SpartaLabs is manufactured by solid-phase peptide synthesis and verified by third-party HPLC and mass spectrometry analysis; further detail on synthesis and batch verification is covered in the MT-II sourcing and quality article.

References

1. Gantz I, Fong TM. The melanocortin system. Am J Physiol Endocrinol Metab. 2003;284(3):E468-74. PMID: 12556347. DOI: 10.1152/ajpendo.00524.2002

2. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992;257(5074):1248-51. PMID: 1325670. DOI: 10.1126/science.1325670

3. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84. PMID: 8637402. DOI: 10.1016/0024-3205(96)00160-9

4. Ryakhovsky VV, Khachiyan GA, Kosovova NF, Isamiddinova EF, Ivanov AS. The first preparative solution phase synthesis of melanotan II. Beilstein J Org Chem. 2008;4:39. PMID: 19043625. DOI: 10.3762/bjoc.4.39

5. Sharma S, Garfield AS, Shah B, Kleyn P, Numao S, Costello DA, Bhatt DL, Kennedy CR. Current Mechanistic and Pharmacodynamic Understanding of Melanocortin-4 Receptor Activation. Molecules. 2019;24(10):1892. PMID: 31100979. PMC: PMC6572030. DOI: 10.3390/molecules24101892

6. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-30. PMID: 16412534. DOI: 10.1016/j.peptides.2005.01.029